ArticleNature communications2025
Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution.
Erratum issuedAbstract read
In one paragraph
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Article
- Article
- Antibody-Based Biologics for CNS Disorders.Antibodies (Basel, Switzerland) · 2026Review
- Breaking Biological Barriers: Engineering Nanocarriers for Efficient Drug and Gene Delivery through Nano-Bio Interfaces and Biophysical Design.Applied physics reviews · 2026Article
- CA-IV-directed small-molecule shuttle enables targeted brain delivery of biologics.Nature chemical biology · 2026Article
- Engineering Protein-Based HIV Entry Inhibitors: Advances, Challenges, and Translational Strategies.Biomolecules · 2026Review
- Systematic Design and Evaluation of Nasal Drug Delivery for Central Nervous System Disease from Experimental to Clinical Application.Pharmaceutics · 2026Review
- Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics.Antibody therapeutics · 2026Review
- Applications of micro/nano drug delivery systems in cancer pain management.Bioactive materials · 2026Review
- Targeting the astrocyte-microglia EFEMP1-GALNT10 axis: a spatially programmable therapeutic strategy for hippocampal vulnerability in Alzheimer's disease.Journal of translational medicine · 2026Article
- Quantitative comparison of methods for widespread delivery of small molecules across the blood-brain barrier.Communications biology · 2026Article
- In-vitro interaction studies between the amyloid PET tracer florbetaben and the amyloid-beta targeting antibodies lecanemab and donanemab on AD brain samples reveal no interferences.Alzheimer's research & therapy · 2026Article
- From Polyphenols to Prodrugs: Bridging the Blood-Brain Barrier with Nanomedicine and Neurotherapeutics.International journal of molecular sciences · 2026Review
- Bioconjugates for improved delivery of oligonucleotide therapeutics to the central nervous system.Advanced drug delivery reviews · 2026Review
- Bridging the blood-brain barrier: strategies to improve delivery of biologics to tumors in the brain.Fluids and barriers of the CNS · 2026Review
- Complement in brain and eye disease: shared mechanisms, convergent pathologies, and common therapeutic opportunities.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Review
- Brain Endothelial Glycocalyx as a Blood-Facing Translational Interface in Alzheimer's Disease: Beyond "Leaky" Barriers Toward Repair-First Stratification.Drug design, development and therapy · 2026Review
- Nanotherapeutic Interventions for Parkinson's Disease: Modulating Pathogenic Mechanisms and Overcoming Therapeutic Obstacles.International journal of nanomedicine · 2026Review
- Molecular design of MRI probes for targeting amyloid-β species: fromTheranostics · 2026Review
- Chimeras co-targeting antigens and FcγRIIb trigger degradation of extracellular soluble proteins and pathological aggregates.Nature communications · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
34 authors.
Nathalie KhouryDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Michelle E PizzoDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.ORCID http://orcid.org/0000-0003-4219-5996
Claire B DiscenzaDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
David JoyDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.ORCID http://orcid.org/0000-0001-9941-9538
David TatarakisDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Mihail Ivilinov TodorovDeep Piction, 81377, Munich, Germany.
Moritz NegwerDeep Piction, 81377, Munich, Germany.
Connie HaDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Gabrielly L De MeloDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Lily SarrafhaDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.ORCID http://orcid.org/0000-0002-6168-2119
Matthew J SimonDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Darren ChanDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Roni ChauDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Kylie S ChewDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.ORCID http://orcid.org/0000-0003-4752-009X
Johann ChowDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.ORCID http://orcid.org/0009-0001-8170-6392
Allisa ClemensDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Yaneth Robles-ColmenaresDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Jason C DugasDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Joseph DuqueDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Doris KalteneckerDeep Piction, 81377, Munich, Germany.
Holly KaneDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Amy LeungDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Edwin LozanoDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Arash MoshkforoushDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Elysia RocheDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Thomas SandmannDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.ORCID http://orcid.org/0000-0002-6601-8890
Mabel TongDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Kaitlin XaDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Yinhan ZhouDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Joseph W LewcockDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.ORCID http://orcid.org/0000-0003-3012-7881
Ali ErtürkDeep Piction, 81377, Munich, Germany.
Robert G ThorneDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
Meredith E K CalvertDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA. calvert@dnli.com.ORCID http://orcid.org/0000-0003-2893-959X
Y Joy Yu ZucheroDenali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA. zuchero@dnli.com.ORCID http://orcid.org/0000-0001-5183-7968
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood brain barrier-crossing molecules targeting transferrin receptor (TfR) and CD98 heavy chain (CD98hc) are widely reported to promote enhanced brain delivery of therapeutics. Here, we provide a comprehensive and unbiased biodistribution characterization of TfR and CD98hc antibody transport vehicles (ATV
Indexed as
Blood-Brain BarrierImmunoglobulin Fc FragmentsReceptors, TransferrinAnimalsBrainFemaleHumansMacaca fascicularisMaleMiceMice, Inbred C57BLSpinal CordTissue DistributionImmunoglobulin Fc FragmentsReceptors, Transferrin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.